# Study of ANA773 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) to Assess Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD)

> **NCT01211626** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 75 (actual)

## Conditions studied

- HCV Infection

## Interventions

- **DRUG:** ANA773
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01211626
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2012-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01211626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01211626, "Study of ANA773 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) to Assess Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01211626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*